C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 71.4% | -33.3% | -32.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 62.7% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -290.5% | -588.3% | -399.7% | -175.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -296% | -638.3% | -412.2% | -183.2% |
| EPS Diluted | -1.52 | -2.67 | -2.62 | -1.82 |
| % Growth | 43.1% | -1.9% | -44% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |